The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells

Yuichi Murakami, Kahori Sonoda, Hideyuki Abe, Kosuke Watari, Daiki Kusakabe, Koichi Azuma, Akihiko Kawahara, Jun Akiba, Chitose Oneyama, Jonathan A. Pachter, Kazuko Sakai, Kazuto Nishio, Michihiko Kuwano, Mayumi Ono

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Second- and third-generation inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity (EGFR-TKIs) are improving the treatment of patients with non-small cell lung cancer. Here we established two sublines (BR1-8 and BR2-3) resistant to a second-generation inhibitor, afatinib, from the human lung cancer cell line HCC827 that harbors a mutation that activates the tyrosine kinase activity of EGFR. These afatinib-resistant sublines were resistant to first-generation EGFR-TKIs, gefitinib and erlotinib, and a third-generation EGFR-TKI, osimertinib. These resistant sublines showed markedly reduced levels of multiple EGFR family proteins, including the activated mutant EGFR, and complete loss of EGFR amplification as compared with their parental HCC827 cells harboring amplification of EGFR gene. Treatment with the multikinase inhibitor dasatinib or transfection with a SRC small interfering RNA inhibited cell survival and AKT phosphorylation in drug-resistant sublines to a greater extent compared with HCC827 cells. Further, the migration of drug-resistant cells was greater compared with that of HCC827 cells and was inhibited by dasatinib or an FAK inhibitor. These findings indicate that compensatory activation of SRC family kinases (SFKs) and FAK supports the survival and migration of afatinib-resistant cells when the expression of multiple EGFR family proteins was mostly abrogated. Combinations of potent drugs that target SFKs and FAK may overcome the resistance of lung cancer cells to second-generation TKIs.

Original languageEnglish
Pages (from-to)70736-70751
Number of pages16
JournalOncotarget
Volume8
Issue number41
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

erbB-1 Genes
Focal Adhesion Protein-Tyrosine Kinases
Epidermal Growth Factor Receptor
Lung Neoplasms
Phosphotransferases
Protein-Tyrosine Kinases
Drug Combinations
Non-Small Cell Lung Carcinoma
Pharmaceutical Preparations
Small Interfering RNA
Transfection
osimertinib
BIBW 2992
Erlotinib Hydrochloride
Cell Survival
Phosphorylation
Cell Line
Mutation
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells. / Murakami, Yuichi; Sonoda, Kahori; Abe, Hideyuki; Watari, Kosuke; Kusakabe, Daiki; Azuma, Koichi; Kawahara, Akihiko; Akiba, Jun; Oneyama, Chitose; Pachter, Jonathan A.; Sakai, Kazuko; Nishio, Kazuto; Kuwano, Michihiko; Ono, Mayumi.

In: Oncotarget, Vol. 8, No. 41, 01.01.2017, p. 70736-70751.

Research output: Contribution to journalArticle

Murakami, Y, Sonoda, K, Abe, H, Watari, K, Kusakabe, D, Azuma, K, Kawahara, A, Akiba, J, Oneyama, C, Pachter, JA, Sakai, K, Nishio, K, Kuwano, M & Ono, M 2017, 'The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells' Oncotarget, vol. 8, no. 41, pp. 70736-70751. https://doi.org/10.18632/oncotarget.19982
Murakami, Yuichi ; Sonoda, Kahori ; Abe, Hideyuki ; Watari, Kosuke ; Kusakabe, Daiki ; Azuma, Koichi ; Kawahara, Akihiko ; Akiba, Jun ; Oneyama, Chitose ; Pachter, Jonathan A. ; Sakai, Kazuko ; Nishio, Kazuto ; Kuwano, Michihiko ; Ono, Mayumi. / The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells. In: Oncotarget. 2017 ; Vol. 8, No. 41. pp. 70736-70751.
@article{457deeb23a2f43619ea11644d7f0adea,
title = "The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells",
abstract = "Second- and third-generation inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity (EGFR-TKIs) are improving the treatment of patients with non-small cell lung cancer. Here we established two sublines (BR1-8 and BR2-3) resistant to a second-generation inhibitor, afatinib, from the human lung cancer cell line HCC827 that harbors a mutation that activates the tyrosine kinase activity of EGFR. These afatinib-resistant sublines were resistant to first-generation EGFR-TKIs, gefitinib and erlotinib, and a third-generation EGFR-TKI, osimertinib. These resistant sublines showed markedly reduced levels of multiple EGFR family proteins, including the activated mutant EGFR, and complete loss of EGFR amplification as compared with their parental HCC827 cells harboring amplification of EGFR gene. Treatment with the multikinase inhibitor dasatinib or transfection with a SRC small interfering RNA inhibited cell survival and AKT phosphorylation in drug-resistant sublines to a greater extent compared with HCC827 cells. Further, the migration of drug-resistant cells was greater compared with that of HCC827 cells and was inhibited by dasatinib or an FAK inhibitor. These findings indicate that compensatory activation of SRC family kinases (SFKs) and FAK supports the survival and migration of afatinib-resistant cells when the expression of multiple EGFR family proteins was mostly abrogated. Combinations of potent drugs that target SFKs and FAK may overcome the resistance of lung cancer cells to second-generation TKIs.",
author = "Yuichi Murakami and Kahori Sonoda and Hideyuki Abe and Kosuke Watari and Daiki Kusakabe and Koichi Azuma and Akihiko Kawahara and Jun Akiba and Chitose Oneyama and Pachter, {Jonathan A.} and Kazuko Sakai and Kazuto Nishio and Michihiko Kuwano and Mayumi Ono",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.19982",
language = "English",
volume = "8",
pages = "70736--70751",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "41",

}

TY - JOUR

T1 - The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells

AU - Murakami, Yuichi

AU - Sonoda, Kahori

AU - Abe, Hideyuki

AU - Watari, Kosuke

AU - Kusakabe, Daiki

AU - Azuma, Koichi

AU - Kawahara, Akihiko

AU - Akiba, Jun

AU - Oneyama, Chitose

AU - Pachter, Jonathan A.

AU - Sakai, Kazuko

AU - Nishio, Kazuto

AU - Kuwano, Michihiko

AU - Ono, Mayumi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Second- and third-generation inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity (EGFR-TKIs) are improving the treatment of patients with non-small cell lung cancer. Here we established two sublines (BR1-8 and BR2-3) resistant to a second-generation inhibitor, afatinib, from the human lung cancer cell line HCC827 that harbors a mutation that activates the tyrosine kinase activity of EGFR. These afatinib-resistant sublines were resistant to first-generation EGFR-TKIs, gefitinib and erlotinib, and a third-generation EGFR-TKI, osimertinib. These resistant sublines showed markedly reduced levels of multiple EGFR family proteins, including the activated mutant EGFR, and complete loss of EGFR amplification as compared with their parental HCC827 cells harboring amplification of EGFR gene. Treatment with the multikinase inhibitor dasatinib or transfection with a SRC small interfering RNA inhibited cell survival and AKT phosphorylation in drug-resistant sublines to a greater extent compared with HCC827 cells. Further, the migration of drug-resistant cells was greater compared with that of HCC827 cells and was inhibited by dasatinib or an FAK inhibitor. These findings indicate that compensatory activation of SRC family kinases (SFKs) and FAK supports the survival and migration of afatinib-resistant cells when the expression of multiple EGFR family proteins was mostly abrogated. Combinations of potent drugs that target SFKs and FAK may overcome the resistance of lung cancer cells to second-generation TKIs.

AB - Second- and third-generation inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity (EGFR-TKIs) are improving the treatment of patients with non-small cell lung cancer. Here we established two sublines (BR1-8 and BR2-3) resistant to a second-generation inhibitor, afatinib, from the human lung cancer cell line HCC827 that harbors a mutation that activates the tyrosine kinase activity of EGFR. These afatinib-resistant sublines were resistant to first-generation EGFR-TKIs, gefitinib and erlotinib, and a third-generation EGFR-TKI, osimertinib. These resistant sublines showed markedly reduced levels of multiple EGFR family proteins, including the activated mutant EGFR, and complete loss of EGFR amplification as compared with their parental HCC827 cells harboring amplification of EGFR gene. Treatment with the multikinase inhibitor dasatinib or transfection with a SRC small interfering RNA inhibited cell survival and AKT phosphorylation in drug-resistant sublines to a greater extent compared with HCC827 cells. Further, the migration of drug-resistant cells was greater compared with that of HCC827 cells and was inhibited by dasatinib or an FAK inhibitor. These findings indicate that compensatory activation of SRC family kinases (SFKs) and FAK supports the survival and migration of afatinib-resistant cells when the expression of multiple EGFR family proteins was mostly abrogated. Combinations of potent drugs that target SFKs and FAK may overcome the resistance of lung cancer cells to second-generation TKIs.

UR - http://www.scopus.com/inward/record.url?scp=85030231441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030231441&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19982

DO - 10.18632/oncotarget.19982

M3 - Article

VL - 8

SP - 70736

EP - 70751

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 41

ER -